Pre-order Enquiry
Request Free Sample
Global Colloids (Blood Plasma) Market Growth 2019-2024
SKU ID : LPI-13806542 | Publishing Date : 01-Feb-2019 | No. of pages : 183
Colloids (blood plasma) are the substances of expanding the circulating blood volume, which mainly contain albumin type, gelatin type, dextran type and hydroxyethyl starch type.
Colloids (Blood Plasma) can be applied for extensive burns, massive blood or plasma loss and hypovolemic shock. In this report, we calculate colloids (blood plasma) preparations, which is produced by albumin, gelatin, dextran and hydroxyethyl starch.
The global colloids (blood plasma) industry is mature. The production of Human Albumin increase from 544.08 MT in 2010 to 805.38 MT in 2015, with an average growth rate of more than 9.60 %. The production of synthetic colloids increase from 42.03 Million Units in 2010 to 53.43 Million Units in 2015, with an average growth rate of more than 5.42 %.
The production growth rate of hydroxyethyl starch colloid reduced obviously because Europe and USA banned the usage of HES solutions in patients with sepsis. At the same time, this stimulated the increase of growth rate in albumin colloids.
The manufacturers and consumers of natural colloids and synthetic colloids are both concentrated in North America, Europe and China. North America is the largest manufacturer and consumer in natural colloids , however Europe occupies the largest share in the global synthetic market.
According to this study, over the next five years the Colloids (Blood Plasma) market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Colloids (Blood Plasma) business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Colloids (Blood Plasma) market by product type, application, key manufacturers and key regions and countries.
This study considers the Colloids (Blood Plasma) value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Natural Type Colloids (Blood Plasma)
Synthetic Type Colloids (Blood Plasma)
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Extensive Burns
Massive Blood or Plasma Loss
Hypovolemic Shock
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
CSL Behring
Baxter
Grifols
Octapharma
Kedrion
Shanghai Raas
CTBB
Hualan Bio
Rongsheng Pharmaceutical
Boya Rongsheng
B. Braun Medical
Fresenius Kabi
HOSPIRA
Axa parenterals
Fresenius Kabi(China)
CR Double-Crane
Kelun Group
Shandong Qidu Pharmaceutical
Shandong Hualu Pharmaceutical
Minsheng Pharma
Kanglepharm
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Colloids (Blood Plasma) consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Colloids (Blood Plasma) market by identifying its various subsegments.
Focuses on the key global Colloids (Blood Plasma) manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Colloids (Blood Plasma) with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Colloids (Blood Plasma) submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Colloids (Blood Plasma) can be applied for extensive burns, massive blood or plasma loss and hypovolemic shock. In this report, we calculate colloids (blood plasma) preparations, which is produced by albumin, gelatin, dextran and hydroxyethyl starch.
The global colloids (blood plasma) industry is mature. The production of Human Albumin increase from 544.08 MT in 2010 to 805.38 MT in 2015, with an average growth rate of more than 9.60 %. The production of synthetic colloids increase from 42.03 Million Units in 2010 to 53.43 Million Units in 2015, with an average growth rate of more than 5.42 %.
The production growth rate of hydroxyethyl starch colloid reduced obviously because Europe and USA banned the usage of HES solutions in patients with sepsis. At the same time, this stimulated the increase of growth rate in albumin colloids.
The manufacturers and consumers of natural colloids and synthetic colloids are both concentrated in North America, Europe and China. North America is the largest manufacturer and consumer in natural colloids , however Europe occupies the largest share in the global synthetic market.
According to this study, over the next five years the Colloids (Blood Plasma) market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Colloids (Blood Plasma) business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Colloids (Blood Plasma) market by product type, application, key manufacturers and key regions and countries.
This study considers the Colloids (Blood Plasma) value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Natural Type Colloids (Blood Plasma)
Synthetic Type Colloids (Blood Plasma)
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Extensive Burns
Massive Blood or Plasma Loss
Hypovolemic Shock
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
CSL Behring
Baxter
Grifols
Octapharma
Kedrion
Shanghai Raas
CTBB
Hualan Bio
Rongsheng Pharmaceutical
Boya Rongsheng
B. Braun Medical
Fresenius Kabi
HOSPIRA
Axa parenterals
Fresenius Kabi(China)
CR Double-Crane
Kelun Group
Shandong Qidu Pharmaceutical
Shandong Hualu Pharmaceutical
Minsheng Pharma
Kanglepharm
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Colloids (Blood Plasma) consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Colloids (Blood Plasma) market by identifying its various subsegments.
Focuses on the key global Colloids (Blood Plasma) manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Colloids (Blood Plasma) with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Colloids (Blood Plasma) submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
